EBS News and Press, Emergent Biosolutions Inc. From 02/19/21

Emergent Biosolutions ([[EBS]] -10.9%) managed to beat consensus estimates in Q4 2020 with the quarterly and yearly revenue rising ~61.8% and ~40.6% YoY, respectively.The revenue from the contract development and manufacturing services, which made up ~29.0% of the 2020 top-line...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Shares of Emergent BioSolutions (NYSE: EBS) were sliding 9.3% lower as of 11:13 a.m. EST on Friday. The decline came after Chardan Capital analyst Keay Nakae downgraded the stock from buy to hold. Nakae set a one-year price target for Emergent Biosolutions of $112, more than 4% belo...

Image source: The Motley Fool. Emergent BioSolutions Inc (NYSE: EBS) Q4 2020 Earnings Call Feb 18, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions Inc (EBS) Q4 2020 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q4 2020 Earnings Conference Call February 18, 2021 05:00 p.m. ET Company Representatives Bob Kramer - President, Chief Executive Officer Rich Lindahl - Chief Financial Officer Syed Husain - Senior Vice President, CDMO Business Unit Head Laura Saward - Senior V...

Emergent Biosolutions (EBS): Q4 Non-GAAP EPS of $3.67 beats by $0.26; GAAP EPS of $3.44 beats by $0.16.Revenue of $583M (+61.8% Y/Y) beats by $7.92M.Press Release For further details see: Emergent Biosolutions EPS beats by $0.26, beats on revenue

Reports record fourth quarter and year to date 2020 performance, in line with prior guidance Reaffirms full year 2021 forecast GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year en...

Adenoviruses have long been used as tools in molecular biology. The first step in this process is to engineer the viral DNA that you need and make a lot of it. It's a fundamentally different process than the mRNA vaccines, with its own features (good and bad). For further de...

GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial ...

Humanigen ([[HGEN]] +0.5%) and Ajinomoto Bio-Pharma Services announce that the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, a Phase 3 treatment option in development for patients hospitalized with COVID-19.Humanigen is actively enrolling ...